| pubmed-article:8640699 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0023443 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0013072 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0065879 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0117234 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0232970 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0055226 | lld:lifeskim |
| pubmed-article:8640699 | lifeskim:mentions | umls-concept:C0443985 | lld:lifeskim |
| pubmed-article:8640699 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:8640699 | pubmed:dateCreated | 1996-7-17 | lld:pubmed |
| pubmed-article:8640699 | pubmed:abstractText | Breast cancer patients with prior response to endocrine therapy achieve subsequent benefit from additional endocrine therapies. The efficacy and safety of an aromatase inhibitor, fadrozole HCL, were compared with megestrol acetate in post menopausal patients who had disease progression after receiving antiestrogen therapy either for metastatic disease or as adjuvant therapy. | lld:pubmed |
| pubmed-article:8640699 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8640699 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8640699 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8640699 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8640699 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8640699 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8640699 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:8640699 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:8640699 | pubmed:author | pubmed-author:SmithRR | lld:pubmed |
| pubmed-article:8640699 | pubmed:author | pubmed-author:CooperJJ | lld:pubmed |
| pubmed-article:8640699 | pubmed:author | pubmed-author:KellerA MAM | lld:pubmed |
| pubmed-article:8640699 | pubmed:author | pubmed-author:VogelCC | lld:pubmed |
| pubmed-article:8640699 | pubmed:author | pubmed-author:BuzdarA UAU | lld:pubmed |
| pubmed-article:8640699 | pubmed:author | pubmed-author:BonomoJJ | lld:pubmed |
| pubmed-article:8640699 | pubmed:author | pubmed-author:MulaghaMM | lld:pubmed |
| pubmed-article:8640699 | pubmed:author | pubmed-author:FavisGG | lld:pubmed |
| pubmed-article:8640699 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8640699 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:8640699 | pubmed:volume | 77 | lld:pubmed |
| pubmed-article:8640699 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8640699 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8640699 | pubmed:pagination | 2503-13 | lld:pubmed |
| pubmed-article:8640699 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:meshHeading | pubmed-meshheading:8640699-... | lld:pubmed |
| pubmed-article:8640699 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8640699 | pubmed:articleTitle | Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials. | lld:pubmed |
| pubmed-article:8640699 | pubmed:affiliation | Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. Multi-Institutional Trialist Study Group. | lld:pubmed |
| pubmed-article:8640699 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8640699 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8640699 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:8640699 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:8640699 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8640699 | lld:pubmed |
